NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 48 filers reported holding NEUROCRINE BIOSCIENCES INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $243,175,000 | -82.0% | 182,000 | -81.8% | 0.00% | -100.0% |
| Q1 2021 | $1,349,940,000 | -79.8% | 1,000,000 | -79.2% | 0.00% | -83.3% |
| Q4 2020 | $6,684,514,000 | -19.0% | 4,808,000 | -19.7% | 0.01% | 0.0% |
| Q3 2020 | $8,256,257,000 | +114.5% | 5,990,000 | +158.3% | 0.01% | +71.4% |
| Q2 2020 | $3,849,354,000 | -72.5% | 2,319,000 | -78.8% | 0.01% | -75.9% |
| Q1 2020 | $13,978,222,000 | +36.4% | 10,950,000 | +63.4% | 0.03% | +52.6% |
| Q4 2019 | $10,248,363,000 | +132.9% | 6,702,000 | +108.9% | 0.02% | +137.5% |
| Q3 2019 | $4,401,216,000 | -21.0% | 3,208,000 | -24.1% | 0.01% | -27.3% |
| Q2 2019 | $5,571,170,000 | -11.6% | 4,225,000 | -9.2% | 0.01% | -21.4% |
| Q1 2019 | $6,303,103,000 | +592.3% | 4,655,000 | +507.7% | 0.01% | +600.0% |
| Q4 2018 | $910,506,000 | +119.6% | 766,000 | +215.2% | 0.00% | +100.0% |
| Q3 2018 | $414,684,000 | +111.7% | 243,000 | +78.7% | 0.00% | – |
| Q2 2018 | $195,881,000 | – | 136,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| III Capital Management | 12,500,000 | $17,262,000 | 3.12% |
| CSS LLC/IL | 24,395,000 | $33,616,000 | 1.59% |
| Mint Tower Capital Management B.V. | 9,000,000 | $12,407,000 | 1.46% |
| Context Partners Fund, L.P. | 3,000,000 | $4,125,000 | 0.90% |
| Context Capital Management, LLC | 3,000,000 | $4,125,000 | 0.90% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,258,000 | $5,971,000 | 0.71% |
| SSI INVESTMENT MANAGEMENT LLC | 5,888,000 | $8,100,000 | 0.70% |
| Aequim Alternative Investments LP | 3,000,000 | $4,155,000 | 0.55% |
| WOLVERINE ASSET MANAGEMENT LLC | 32,181,000 | $44,437,000 | 0.40% |
| TWO SIGMA SECURITIES, LLC | 13,000,000 | $17,875,000 | 0.36% |